<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03054220</url>
  </required_header>
  <id_info>
    <org_study_id>2016-00262</org_study_id>
    <nct_id>NCT03054220</nct_id>
  </id_info>
  <brief_title>Impact of Genetic Polymorphism on Drug-Drug Interactions Involving CYP2D6</brief_title>
  <official_title>Risk of Phenoconversion in Genetic Extensive Metabolizers Healthy Volunteers Carriers of One Fully-Functional and One Non-Functional Allele Versus Carriers of Two Fully-Functional Alleles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Desmeules</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CYP2D6 is characterized by a huge variability in the general population, mainly because of&#xD;
      genetic polymorphism and drug-drug interactions (DDIs). CYP2D6 genotype is known to have an&#xD;
      impact on the extent of DDIs. Indeed several studies have pointed out differential DDIs&#xD;
      extent according to CYP2D6 genotype. The terms phenoconversion and phenotype switch are both&#xD;
      used to describe the phenomenon by which a given subject changes his phenotype to another due&#xD;
      external influence such as DDIs. When given a sufficiently strong CYP2D6 inhibitor, the&#xD;
      phenotype of an individual with no mutant allele (extensive metabolizer, EM) of CYP2D6 can be&#xD;
      modified to a poor metabolizer (PM) phenotype. This vulnerability is also thought to be&#xD;
      dependent on CYP2D6 genotype. Various combinations of alleles predict an EM genotype, which&#xD;
      represents about 60 to 70% of the general population. The aim of the study is to determine&#xD;
      whether the presence of genetic mutation in CYP2D6 has an impact on DDIs involving the CYP2D6&#xD;
      enzyme. Our interest focuses on CYP2D6 EM carriers of two fully functional alleles and&#xD;
      carriers of one non-functional and one functional allele. In order to elucidate this&#xD;
      question, CYP2D6 activity will be measured on healthy volunteers by administration of single&#xD;
      low doses of dextromethorphan and tramadol in presence or not of duloxetine and paroxetine,&#xD;
      two known CYP2D6 inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the proportion of volunteers with urinary metabolic ratio Dextromethorphan/Dextrorphan &gt;0.3</measure>
    <time_frame>10 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of plasmatic concentrations probe drugs (dextromethorphan and tramadol) and their metabolites and tramadol) and their metabolites in plasma</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of probe drugs (dextromethorphan and tramadol) and their metabolites and tramadol) and their metabolites in plasma and tramadol) and their metabolites in plasma</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of plasmatic concentrations probe drugs (dextromethorphan and tramadol) and their metabolites and tramadol) and their metabolites in plasma and tramadol) and their metabolites in plasma</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of probe drugs (dextromethorphan and tramadol) and their metabolites and tramadol) and their metabolites in plasma and tramadol) and their metabolites in plasma</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of probe drugs (dextromethorphan and tramadol) and their metabolites and tramadol) and their metabolites in plasma</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the urinary metabolic ratio tramadol/M1</measure>
    <time_frame>10 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CYP2D6 gene score 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carriers of 1 fully functional and 1non functional CYP2D6 alleles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2D6 gene score 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carriers of 2 fully functional CYP2D6 alleles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan 5 MG</intervention_name>
    <arm_group_label>CYP2D6 gene score 1</arm_group_label>
    <arm_group_label>CYP2D6 gene score 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol 10 mg</intervention_name>
    <arm_group_label>CYP2D6 gene score 1</arm_group_label>
    <arm_group_label>CYP2D6 gene score 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 60mg</intervention_name>
    <arm_group_label>CYP2D6 gene score 1</arm_group_label>
    <arm_group_label>CYP2D6 gene score 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine 20 mg</intervention_name>
    <arm_group_label>CYP2D6 gene score 1</arm_group_label>
    <arm_group_label>CYP2D6 gene score 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women&#xD;
&#xD;
          -  Age 18-60 years&#xD;
&#xD;
          -  Body Mass Index 18-27&#xD;
&#xD;
          -  Understanding of French language and able to give a written inform consent&#xD;
&#xD;
          -  CYP2D6 genotype : combination of two fully-functional (normal activity) alleles or of&#xD;
             one fully-functional and one non-functional allele (null activity), according to table&#xD;
             1, without gene multiplication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Any pathologies, use of drugs or food that may affect CYP2D6 activity&#xD;
&#xD;
          -  Regular smokers of &gt;5 cigarettes/day&#xD;
&#xD;
          -  Renal or hepatic impairment&#xD;
&#xD;
          -  Medical history of chronic alcoholism or abuse of psychoactive drugs, including opiate&#xD;
             addiction&#xD;
&#xD;
          -  Liver transplantation&#xD;
&#xD;
          -  Sensitivity to any of the drugs used&#xD;
&#xD;
          -  Alteration of hepatic tests more than 2x normal&#xD;
&#xD;
          -  Glomerular filtration rate &lt; 60 ml/min/1.73m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jules A Desmeules, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>HUG</affiliation>
  </overall_official>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Jules Desmeules</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

